Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss

Drug Targets GLP-1 And Glucagon Receptors

 
• By Mandy Jackson
  
Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D